Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human cytomegalovirus (HCMV), also known as human herpesvirus 5 (HHV-5), is a ubiquitous virus that belongs to the Herpesviridae family. It establishes lifelong latency after primary infection and can reactivate under immunosuppressed conditions. HCMV infection is widespread, with prevalence varying by region. While often asymptomatic in healthy individuals, HCMV can cause severe disease in immunocompromised patients and congenital defects if transmitted to a fetus. Recent research suggests a potential oncomodulatory role for certain HCMV strains in cancer development. There is currently no vaccine, and antiviral treatments are used to manage severe disease.
Antiviral drugs inhibit viral DNA polymerase or other viral enzymes essential for replication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human cytomegalovirus (HCMV).